Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine

Neuroscience Letters

Volumn 413, Issue 1, 2007, Pages 68-71

  Buccafusco, Jerry J ^a,b   Shuster, Laura C ^a,b   Terry Jr , Alvin V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylcholine receptors; Desensitization; Ganglionic nicotinic receptors; Mean arterial blood pressure; Nicotine metabolites

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; CHOLINERGIC RECEPTOR; COTININE; DRUG METABOLITE; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; MALE; MEAN ARTERIAL PRESSURE; METABOLITE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

ANIMALS; BLOOD PRESSURE; COTININE; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GANGLIONIC STIMULANTS; MALE; NICOTINE; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 33846414011     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.11.028     Document Type: Article

References (17)

1. Abbruscato T.J., Lopez S.P., Mark K.S., Hawkins B.T., and Davis T.P. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91 (2002) 2525-2538
2. Briggs C.A., and McKenna D.G. Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37 (1998) 1095-1102
3. Briggs C.A., McKenna D.G., Monteggia L.M., Touma E., Roch J.M., Arneric S.P., Gopalakrishnan M., and Sullivan J.P. Gain of function mutation of the α7 nicotinic receptor: distinct pharmacology of the α7V242T variant. Eur. J. Pharmacol. 366 (1999) 301-308
4. Buccafusco J.J. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol. Interv. 4 (2004) 285-295
5. Buccafusco J.J., and Jackson W.J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12 (1991) 233-238
6. Buccafusco J.J., Jackson W.J., Terry Jr. A.V., Marsh K.C., Decker M.W., and Arneric S.P. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120 (1995) 256-266
7. Buccafusco J.J., Letchworth S.R., Bencherif M., and Lippillo P.M. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol. Sci. 26 (2005) 352-360
8. 3H]dopamine release from mouse striatal synaptosomes and response to chronic L-nicotine treatment. J. Pharmacol. Exp. Ther. 282 (1997) 232-243
9. Guan Z.Z., Miao H., Tian J.Y., Unger C., Nordberg A., and Zhang X. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J. Neural Trans. 108 (2001) 1417-1433
10. Hatsukami D.K., Grillo M., Pentel P.R., Oncken C., and Bliss R. Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol. Biochem. Behav. 57 (1997) 643-650
11. Jonnala R.R., and Buccafusco J.J. Relationship between cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. 66 (2001) 565-572
12. Li X.D., and Buccafusco J.J. Effect of beta-amyloid peptide 1-42 on the cytoprotective action mediated by α7 nicotinic acetylcholine receptors in growth factor-deprived differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 307 (2003) 670-675
13. Lockman P.R., McAfee G., Geldenhuys W.J., Van der Schyf C.J., Abbruscato T.J., and Allen D.D. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J. Pharmacol. Exp. Ther. 314 (2005) 636-642
14. Lukas R.J. Effects of chronic nicotinic ligand exposure on functional activity of nicotinic acetylcholine receptors expressed by cells of the PC12 rat pheochromocytoma or the TE671/RD human clonal line. J. Neurochem. 56 (1991) 1134-1145
15. 3H]dopamine form rat striatal synaptosomes. Neurosci. Lett. 189 (1995) 171-175
16. Terry Jr. A.V., Hernandez C.M., Hohnadel E.J., Bouchard K.P., and Buccafusco J.J. Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 11 (2005) 229-252
17. Vainio P.J., and Tuominen R.K. Cotinine binding to nicotinic acetylcholine receptors in bovine chromafin cell and rat brain membranes. Nicotine Tob. Res. 3 (2001) 177-182